Loading company…
Zavante Therapeutics develops antibiotics for serious infections in hospitalized patients, including multi-drug resistant bacteria.
Zavante Therapeutics is developing ZOLYD (fosfomycin for injection), an investigational antibiotic for multi-drug resistant infections in hospitalized patients, mainly complicated urinary tract infections. Founded in 2015 and headquartered in San Diego, US, the company is at the Series A stage. It has raised USD 45.00 mn through 5 rounds, most recently a Venture Debt round of USD 10.00 mn led by Square 1 Bank, and Nabriva Therapeutics GmbH acquired it in July 2018.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in